Concr has initiated the VISION trial to use digital twins for predicting breast cancer outcomes in patients with early-stage Triple Negative Breast Cancer (TNBC). The trial leverages Concr’s FarrSight®-Twin technology to integrate genomic data, whole-slide imaging, and clinical data to create individualized digital twins, aiming to improve treatment stratification and predict responses to chemotherapy and immunotherapy.
“While much of the dialogue surrounding AI in healthcare focuses on its potential, we must not overlook the fact that AI tools can – and do – deliver tangible benefits to patients today. VISION is testing a novel individualised care approach designed by clinicians, leveraging latest technology alongside existing diagnostic tests, to facilitate rapid adoption.”
– said Dr. Irina Babina, CEO of Concr.
Discover more here.